Catalyst

Slingshot members are tracking this event:

FDA PDUFA decision on Adamas; (ADMS) ADS-5102, a treatment for levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, set for August 24th

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ADMS Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 24, 2017
Occurred Source:
Related Projects Image
Related Keywords Levodopa, Dyskinesia, Ads-5102, Parkinson’s Disease, Pdufa